The Abu Dhabi Bone Marrow Transplant (AD-BMT©) Program at ADSCC provides an extensive and integrated ecosystem designed for carrying out advanced research and cellular therapy, while ensuring accessibility patients in UAE and the region. Launched in 2020, the AD-BMT© Program was designed as the first comprehensive program to provide autologous and allogeneic hematopoietic stem cells transplant (HSCT) for adults and pediatric patients in the UAE. Conditions include blood cancers, hereditary diseases and autoimmune diseases such as Multiple Sclerosis.
The AD-BMT© Program’s holistic service model includes:
Bone Marrow Transplant also referred to as Hematopoietic Stem Cells Transplantation is a medical procedure performed to replace bone marrow that has been damaged or destroyed by a disease, infection, or chemotherapy. This procedure involves transplanting healthy blood stem cells, which travel to the bone marrow where they produce new blood cells and promote growth of new marrow. At ADSCC, bone marrow transplantation is performed in patients diagnosed with malignant diseases, including leukemia, lymphoma and multiple myeloma.
The main types of hematological cancers for both children and adults are:
In addition, ADSCC’s AD-BMT© program offers Extracorporeal Photopheresis (ECP), the first in the UAE to use this treatment, for Graft-Versus-Host Disease (GvHD). This is a medical complication that can occur after a patient receives a donor’s stem cells or bone marrow transplant.
ADSCC’s AD-BMT© program was awarded as Center of Excellence by the Department of Health – Abu Dhabi in March 2023 for the first time in the UAE.